Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “hold” rating reaffirmed by Deutsche Bank in a research note issued on Friday.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.04% on Friday, hitting $47.68. 2,687,318 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of $46.01 and a one year high of $56.73. The stock’s 50-day moving average is $49.97 and its 200-day moving average is $53.23. The company has a market cap of $114.5 billion and a P/E ratio of 14.83.

GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.71 by $0.06. Analysts expect that GlaxoSmithKline plc will post $3.30 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, October 2nd. Stockholders of record on Friday, August 8th will be given a dividend of $0.6482 per share. This represents a $2.59 dividend on an annualized basis and a yield of 5.44%. The ex-dividend date of this dividend is Wednesday, August 6th.

Several other analysts have also recently commented on the stock. Analysts at Argus cut their price target on shares of GlaxoSmithKline plc from $65.00 to $55.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Separately, analysts at Galvan Research reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Finally, analysts at Mainfirst downgraded shares of GlaxoSmithKline plc to an “underperform” rating in a research note on Monday, July 28th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $52.67.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.